| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.6 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |